Shots:

• The US FDA has approved the IND application of oral Asieris’ APL-1202 + BeiGene's tislelizumab as neoadjuvant therapy in patients with MIBC
• The P-I/II study will evaluate the safety of the dual regimen in MIBC patients- determine the RP2D and assess the efficacy of combo as neoadjuvant therapy for MIBC. Asieris will accelerate the initiation of the clinical trial enrollment in the US and will file CTA to the NMPA in future
• APL-1202 is a reversible MetAP2 Inhibitor with anti-angiogenic- anti-tumor activities- modulating the tumor immune microenvironment- currently being evaluated in a P-III study as 1L treatment for NMIBC in China

  | Ref: PR Newswire | Image: Linkedin